Analysts Set Expectations for Vaxcyte FY2025 Earnings

Vaxcyte, Inc. (NASDAQ:PCVX) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Vaxcyte in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen anticipates that the company will post earnings of ($7.02) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Vaxcyte’s current full-year earnings is ($4.14) per share.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period last year, the firm earned ($0.91) earnings per share.

Several other research analysts have also recently issued reports on PCVX. Needham & Company LLC restated a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a report on Wednesday, November 6th. The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 target price on the stock. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $145.71.

Vaxcyte Trading Down 1.7 %

Vaxcyte stock opened at $86.64 on Thursday. The company has a fifty day simple moving average of $87.29 and a 200-day simple moving average of $93.88. The stock has a market cap of $10.80 billion, a P/E ratio of -18.83 and a beta of 0.98. Vaxcyte has a 12-month low of $58.10 and a 12-month high of $121.06.

Insider Activity

In related news, CEO Grant Pickering sold 15,000 shares of the stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $106.82, for a total value of $1,602,300.00. Following the completion of the transaction, the chief executive officer now owns 435,219 shares of the company’s stock, valued at approximately $46,490,093.58. This represents a 3.33 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Teri Loxam sold 6,250 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the transaction, the director now owns 7,175 shares of the company’s stock, valued at approximately $610,664.25. This trade represents a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 85,982 shares of company stock worth $8,108,425 over the last 90 days. Company insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Vaxcyte

Institutional investors and hedge funds have recently made changes to their positions in the company. Riverview Trust Co acquired a new stake in shares of Vaxcyte in the 3rd quarter worth approximately $27,000. Blue Trust Inc. increased its position in shares of Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after purchasing an additional 93 shares during the period. Meeder Asset Management Inc. raised its stake in shares of Vaxcyte by 1,007.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock worth $80,000 after buying an additional 635 shares in the last quarter. Nomura Asset Management Co. Ltd. acquired a new stake in shares of Vaxcyte in the third quarter valued at $92,000. Finally, Signaturefd LLC grew its holdings in Vaxcyte by 51.9% during the third quarter. Signaturefd LLC now owns 1,048 shares of the company’s stock worth $120,000 after acquiring an additional 358 shares during the period. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.